Few studies have been conducted to evaluate the efficacy of HAIC using circulating tumour cells (CTCs). In this study, a total of 100 patients who received HAIC treatment and CTC detection were selected. The results showed that after HAIC treatment, the levels of CTC, carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) decreased. Postoperative progression-free survival (PFS) rates between patients with positive and negative preoperative CTC results, and for CA19-9, CEA were significantly different. The positive rate of CTCs was 61% before chemotherapy and 23% after chemotherapy, and the correlation coefficient between the two was 0.385. Those whose CTC values increased after chemotherapy had shorter PFS rates. CTCs are an independent predictor of recurrence. Patients with CTC-positive results are more susceptible to recurrence. The CTC count in peripheral blood has a close bearing on the postoperative chemotherapy efficacy of patients with CRC and affects patients' PFS.
Keyphrases
- circulating tumor cells
- free survival
- end stage renal disease
- peripheral blood
- induced apoptosis
- patients undergoing
- circulating tumor
- newly diagnosed
- ejection fraction
- locally advanced
- chronic kidney disease
- peritoneal dialysis
- cell cycle arrest
- squamous cell carcinoma
- patient reported outcomes
- magnetic resonance imaging
- signaling pathway
- rectal cancer
- magnetic resonance
- low dose
- loop mediated isothermal amplification